Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization

Background DNA sequence amplifications are involved in the progression of many tumor types, and have also been found in advanced prostate cancer. The aim of this study was to detect new loci of DNA amplifications in prostate cancer. Methods Comparative genomic hybridization (CGH) was used for whole...

Full description

Saved in:
Bibliographic Details
Published in:The Prostate 2001-02, Vol.46 (3), p.184-190
Main Authors: El Gedaily, Ahmed, Bubendorf, Lukas, Willi, Niels, Fu, Wenting, Richter, Jan, Moch, Holger, Mihatsch, Michael J., Sauter, Guido, Gasser, Thomas C.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
amplification
Biological and medical sciences
CGH
Chromosome Deletion
Disease Progression
DNA, Neoplasm - genetics
Gene Amplification
genetic
hormone-refractory
Humans
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Nucleic Acid Hybridization
prostate cancer
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background DNA sequence amplifications are involved in the progression of many tumor types, and have also been found in advanced prostate cancer. The aim of this study was to detect new loci of DNA amplifications in prostate cancer. Methods Comparative genomic hybridization (CGH) was used for whole genome screening of DNA sequence copy number alterations in 27 advanced prostate cancers. Results The most prevalent changes were losses of 8p, 13q (52%, each), 6q (48%), 18q (37%), 5q (30%), 2q, 4q and 16q (26%, each), and gains of 8q (48%), Xq (40%), and Xp (26%). In addition, 16 high‐level amplifications were found. These included Xq12 (five), 8q24 (two), and 11q13 (one) with known putative target genes (androgen receptor, MYC and Cyclin D1), and 1q21‐25 (three), 10q22 (two), 17q23‐24 (two), and 8q21 (one) where the target genes remain unknown. Conclusions High‐level amplifications at different chromosomal sites occur in advanced prostate cancer. The detection of amplified chromosomal regions may serve as a starting point to discover novel oncogenes involved in prostate cancer progression. Prostate 46:184–190, 2001. © 2001 Wiley‐Liss, Inc.
ISSN:0270-4137
1097-0045
DOI:10.1002/1097-0045(20010215)46:3<184::AID-PROS1022>3.0.CO;2-8